Therapeutic Antibodies

IgE antibodies
#Allergy #Antibody discovery workflow #Engineered antibodies #Genomics #IgE antibodies #Immunotherapy #Monoclonal antibodies

Harnessing the power of IgE antibodies to create novel therapeutics

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this biotech… Read More

Webinar date:
Brought to you by SPT Labtech
#News

Synthetic DNA
#AI #Antibodies #Biotechnology #Drug development #Drug discovery #Synthetic biology #Synthetic DNA #Synthetic libraries

Synthetic biology tools advancing and accelerating drug discovery efforts

Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery.  The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. It has made its… Read More

#Exclusive Content

#Antibody discovery workflow #B cell diversity #Monoclonal antibodies

How to accelerate the discovery of novel antibodies for drug discovery

Download the exclusive free webinar: Accessing Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies. Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. Anupam Singhal, Director… Read More

Webinar date:
Brought to you by Berkeley Lights
#Editor's Choice #News

Monoclonal antibodies
#Cancer #Cancer immunotherapy #Cancer research #Monoclonal antibodies #Oncology #Phase I trial

Phase I trial of lead antibody candidate launched

DynamiCure has dosed the first patients in its Phase I clinical trial evaluating the first of the company’s two anti-CD93 monoclonal antibody candidates, DCBY02, in adults with a wide range of advanced cancers.  CD93 is a novel target downstream of VEGF-A (vascular endothelial growth factor) that has been shown… Read More

#Cancer Research #News

#Biologics #Cell and gene therapy #Clinical research #Comment #FDA #Regulatory

The significance of FDA industry guidance on cell and gene therapies 

On 4 November 2022, the FDA’s Center for Biologics Evaluation and Research released guidance for the industry on studying multiple versions of a cellular or gene therapy (CGT) product in an early-phase clinical trial in a single disease1. This guidance finalises the draft guidance of the same title dated September… Read More

#Exclusive Content #Opinion #Regulatory

Biomarkers concept
#Antibodies #Biomarkers #Cell signalling #Cellular imaging #Microsystems

Data collection that empowers scientific discoveries 

Leica Microsystems and Cell Signaling Technology (CST) have announced a partnership to validate CST antibodies on the Cell DIVE multiplexed imaging solution, allowing researchers to design custom antibody biomarker panels.    Backed by a decade of research, the Cell DIVE iterative staining workflow enables the visualisation of over… Read More

#News

#Covid-19 #Covid-19 vaccine #Drug development #Drug discovery #Gene therapy #Geographic atrophy #Malaria #Monoclonal antibodies #Psychedelics #Treatment-resistant depression

This week in drug discovery (31 October – 4 November)

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Meanwhile, the quest to understand… Read More

#News

#Antibodies #Biologics #Data #Drug design #Exscientia

Exscientia extends capabilities beyond small molecules 

Throughout 2022, Exscientia has progressed AI-driven capabilities for virtual biologics design, such as human antibodies, and is now establishing an automated biologics laboratory in Oxford to internally generate and profile novel antibodies.   Context  Current approaches to optimise antibodies, even those that use machine learning, still… Read More

#News

Mosquito against yellow background
#Malaria #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases #Phase II trial #Sub-Saharan Africa

Monoclonal antibody could transform malaria prevention

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa.   The antibody was up to 88.2% effective at preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can… Read More

#News #Trending News

Antibodies
#Antibodies #Antibody binding #Flow Cytometry #T cell activation #Whitepaper

Accelerate cancer and infectious disease workflows

Download this new whitepaper from Sartorius to understand the unique benefits of the high-throughput iQue Advanced Flow Cytometry Platform, combined with built-in, visual-based iQue Forecyt software, in the antibody discovery workflow. Learn analysis details of: Antibody binding Antibody internalisation and viability ADCP measurement in adherent cells ADCP measurement… Read More

#News

#Antibodies #Antibody binding #Flow Cytometry #T cell activation #Whitepaper

High throughput, multi-parametric analysis accelerates antibody discovery workflows

In this whitepaper, we present the unique benefits of the high-throughput iQue®Advanced Flow Cytometry Platform, combined with built-in, visual-based iQue Forecyt®software, in the antibody discovery workflow. Learn analysis details of: Antibody Binding Antibody Internalisation and Viability ADCP Measurement in Adherent Cells ADCP Measurement in Suspension Cells Quantification of NK Cell-Mediated… Read More

#Intelligence #Resources

#Biomarkers #Cancer research #Click chemistry #Covid-19 #Drug development #Drug discovery #Epstein-Barr virus #Monoclonal antibodies #mRNA #Oncology #Our Future Health #Pancreatic cancer

This week in drug discovery (24-28 October)

News round-up for 24-28 October by DDW Digital Content Editor Diana Spencer  Over the last seven days we’ve seen discoveries that could lead to new treatments for Covid-19, pancreatic cancer and Epstein-Barr virus, as well as the launch of the UK’s largest health research programme and the innovative application of… Read More

#News

Epstein-Barr Virus
#Drug development #Drug discovery #Epstein-Barr virus #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases

Experimental monoclonal antibodies block EBV infection

A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) have been shown to block infection when tested in human cells in a laboratory setting.  One of the experimental mAbs provided nearly complete protection against EBV infection and lymphoma when tested in… Read More

#News

HIV cell and antibodies
#Antibodies #Antivirals #HIV

Trial results support potential new therapeutic approach to HIV 

Positive study findings for N6LS, an investigational, broadly neutralising antibody (bNAb), could indicate a potential new approach for the treatment of HIV.  ViiV Healthcare, a specialist HIV company owned by GSK, Pfizer and Shionogi, presented positive findings from its Phase IIa proof-of-concept study of N6LS at the… Read More

#News

Flow cytometry
#Antibodies #Diagnostics #Drug discovery #Flow Cytometry

Leveraging flow cytometry in drug discovery 

Listen to this article on the DDW podcast: Dr Miguel A Tam, and Dr Kenta Yamamoto, BioLegend, examine the evolution, trends and best practices for smooth and efficient workflows for flow cytometry.  Flow cytometry is a well-established analytical technique that has been supporting reliable diagnostics and… Read More

#News

Antibodies attacking cancer cell
#Bispecific Antibodies #Cancer research #Cancer treatment #Mergers and acquisitions #Monoclonal antibodies #Oncology

Jazz acquires rights to HER2-targeted bispecific antibody

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. Zymeworks will receive a $50 million upfront payment, a second payment of $325 million, at Jazz’s option, and further potential… Read More

#Cancer Research #News